Emergent BioSolutions | EBS - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Akebia Therapeutics USD -11.24M 12.39M 2025-12
ALKERMES USD -61.93M 122.3M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 31.48M 18.04M 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Coherus Biosciences USD -46.35M 90.86M 2025-12
Exelixis USD 267.69M 15M 2026-03
Glaxosmithkline GBP 2.14B 312M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114M 21M 2026-06
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Lexicon Pharmaceuticals USD -12.77M 16.02M 2025-09
Lonza CHF 624M 197M 2024-12
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Myriad Genetics USD 4.6M 3.4M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Pacira USD 571K 8.95M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sanofi EUR 2B 3.16B 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12